This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark

  • May 25, 2026

  • 7 min

Share

Clinical Scorecard: This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark

At a Glance

CategoryDetail
ConditionDuchenne muscular dystrophy
Key MechanismsAAV microdystrophin gene therapy
Target PopulationPatients with Duchenne muscular dystrophy
Care SettingClinical trial setting

Key Highlights

  • 93% of evaluable participants achieved at least 10% microdystrophin expression at week 12.
  • Editing was sustained for at least three months after the last dose.
  • No serious adverse events or clinically meaningful liver test elevations reported.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Evaluable participants in the AFFINITY DUCHENNE trial

          One-time AAV microdystrophin gene therapy

          Clinical Best Practices

            Related Resources & Content

              Original Source(s)

              Related Content